Pacific Shuanglin Bio-pharmacy Co., LTD
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Paisi Shuanglin Biopharmaceutical Co., Ltd. was founded in 1995 and is the core enterprise of the listed company "Pailin Biotech" (stock code 000403). It is a high-tech enterprise that integrates research and development, production, and sales of blood products. It is also a designated production enterprise for blood products that has passed the national GMP certification. Formerly known as the Navy Haiyao Biological Products Research Institute (also known as the Navy Logistics Department Blood Supply Station); In 1998, it implemented relevant central policies and was merged into the Sanjiu Group under the jurisdiction of "Sanjiu Biochemical". In June 1998, it was renamed Sanjiu Group Zhanjiang Development Zone Shuanglin Pharmaceutical Co., Ltd; In 2004, Sanjiu Group implemented a corporate restructuring and transferred Sanjiu Biochemical to Shanxi Zhenxing Group, which became the direct controlling shareholder of Sanjiu Biochemical; In June 2008, Shuanglin Company completed its restructuring and was renamed Guangdong Shuanglin Biopharmaceutical Co., Ltd; In 2018, the two major shareholders of "Zhejiang Mintou" and "Jiazhaoye" settled in the listed company "Zhenxing Biochemical", and "Zhejiang Mintou" became the largest shareholder; In 2019, the listed company completed a name change, with the company name changed from "Zhenxing Biochemical Co., Ltd." to "Southern Shuanglin Biopharmaceutical Co., Ltd.", and the securities abbreviation changed from "Zhenxing Biochemical" to "Shuanglin Biotech". The company currently mainly produces 7 varieties of blood products with a total of 17 specifications, listed in 6 provincial-level high-tech product catalogs, and has 16 drug approval numbers issued by the National Food and Drug Administration. It is one of the enterprises in the same industry in China with a high comprehensive utilization rate of plasma, complete varieties, and reasonable structure. Intravenous injection of human immunoglobulin (pH4) is a product of the national "Key Torch Program" project. Rabies patient immunoglobulin was designated as a rabies prevention medication for the "2008 Beijing Olympics", and all products of the company are national patented process products. After more than 20 years of steady development and standardized operation, the company has a total asset of 1.8 billion yuan and has 13 single plasma collection stations. The annual output value has been growing rapidly in a stepped manner since 2007, ranking among the forefront of the same industry in China. Its comprehensive strength has entered the top ten biopharmaceutical industries in Guangdong Province. |
| Headquarter | Taiyuan |
| Establish Date | 5/22/1995 |
| Listed Code | 000403.SZ |
| Listed Date | 6/28/1996 |
| Chairman | Fu Shaolan. |
| CEO | Yuan Huagang. |
| Website |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
